Drug Profile
Baricitinib - Eli Lilly and Company/Incyte Corporation
Alternative Names: INCB 028050; INCB 28050; LY 3009104; OlumiantLatest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Developer Eli Lilly; Eli Lilly and Company; Incyte Corporation; Natco Pharma
- Class Acetonitriles; Anti-inflammatories; Antipsoriatics; Antirheumatics; Azetidines; Eye disorder therapies; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
- Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors; TYK2 kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Alopecia areata; Atopic dermatitis; Rheumatoid arthritis
- Registered COVID 2019 infections
- Phase III Juvenile rheumatoid arthritis; Uveitis
- Phase II/III Aicardi-Goutieres syndrome; Hereditary autoinflammatory diseases
- Phase II Giant cell arteritis; Myositis; Polymyalgia rheumatica; Primary biliary cirrhosis; Systemic lupus erythematosus
- Discontinued Diabetic nephropathies; Psoriasis; Psoriatic arthritis
Most Recent Events
- 30 Jan 2024 Registered for Alopecia areata in Canada (PO)
- 25 Sep 2023 University of Manchester in collaboration with Eli Lilly and Company completes phase-II MYOJAK trial in Myositis in United Kingdom (PO) (EudraCT2019-003868-42) (NCT04208464)
- 30 Aug 2023 Eli Lilly and Company completes a phase II trial in Polymyalgia rheumatica in France (PO, Tablet) (NCT04027101)